Cargando…

MON-413 First Reported Case of Combined High-Dose Mifepristone Therapy and Oral Contraceptive in Inducing Reversible Cholestatic Hepatitis in a Patient with Cushing Disease

Background: Cushing syndrome is predisposed to hepatocellular disease due to increased visceral fat resulting in NAFLD, and direct effects of medical therapy, notably ketoconazole. Mifepristone (MIFE) (a competitive glucocorticoid receptor antagonist) is a CYP3A4 inhibitor, whereas loestrin (an oral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Youssef, Nancy, Reynolds, Justin, Yuen, Kevin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551021/ http://dx.doi.org/10.1210/js.2019-MON-413

Ejemplares similares

MON-404 Reversible Dilated Cardiomyopathy in a Severe Case of Cushing’s Disease
por: Valente do Couto, Hugo, et al.
Publicado: (2019)

SUN-413 Dual Endocrinopathies Following Single Dose of Pembrolizumab Therapy
por: Parikh, Tanvi, et al.
Publicado: (2019)

MON-328 Disorders of Glucose Metabolism in Cushing Syndrome in Uzbekistan
por: Narimova, Gulchekhra Djumaniyazovna, et al.
Publicado: (2020)

ODP322 Impact of Mifepristone on Liver Function and Resolution of Liver Steatosis in Patients with Cushing Syndrome – A Case Study
por: East, Honey E, et al.
Publicado: (2022)

MON-LB58 The Use of 11C Methionine PET CT In Localization of ACTH Dependent Cushing’s Disease
por: ElEbrashy, Shady Ibrahim, et al.
Publicado: (2020)

MON-412 Subclinical Cushing's Disease and the Importance of Broad Differential Diagnoses
por: Walker, Michelle, et al.
Publicado: (2019)

MON-461 Drug Repurposing to Explore Novel Treatment for Cushing Disease
por: Zhang, Dongyun, et al.
Publicado: (2019)

MON-403 Osteoporosis: A Frequently Neglected Consequence of Cushing's Disease
por: Pedro, Jorge, et al.
Publicado: (2019)

MON-405 Cushing's Disease: An Oligosymptomatic Patient with ACTH-Secreting Pituitary Macroadenoma
por: Manrique Franco, Katty, et al.
Publicado: (2019)

MON-321 AgRP and Food Cravings Decrease with Treatment of Cushing’s Disease
por: Haseltine, Katherine N, et al.
Publicado: (2020)

MON-329 Diagnostic Utility of Overnight High Dose Dexamethasone Suppression Test for Differentiating the Etiology of ACTH Dependent Cushing’s Syndrome
por: Yadav, Subhash B, et al.
Publicado: (2020)

MON-318 Acute, Life-Threatening and Perioperative Complications in Cushing’s Syndrome: Predictors and Outcomes
por: Schernthaner-Reiter, Marie Helene, et al.
Publicado: (2020)

MON-312 The Effects of Cabergoline in Pre-Surgical and Recurrence Periods of Cushing’s Disease Patients
por: Pereira, Ana Julia Garcia, et al.
Publicado: (2020)

SUN-460 Anticipating Hypokalemia in Patients With ACTH-Dependent Cushing Syndrome Treated With Mifepristone: Utilization of Cortisol and ACTH Levels to Identify At-Risk Patients
por: Moraitis, Andreas, et al.
Publicado: (2019)

MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease
por: Yuen, Kevin, et al.
Publicado: (2019)

MON-435 The Responsiveness To Ddavp Test Predicts Usp8 Mutation In Patients With Cushing's Disease
por: Shichi, Hiroki, et al.
Publicado: (2019)

MON-408 Development of Rapidly Progressive Cushing's Disease Following Pituitary Apoplexy Several Years Prior
por: Ortegon Zambrano, Pilar, et al.
Publicado: (2019)

MON-411 Psychological Disturbance And Weight Gain; Early Identification Of Cushing’S Disease In A Teenage Patient.
por: Hasan, Sana
Publicado: (2019)

MON-LB078 Desmopressin Stimulated Salivary Cortisol as a Suplementary Tool in the Diagnosis of Cushing's Syndrome
por: Firme, Ricardo
Publicado: (2019)

MON-457 One in Five Patients Develop Multiple Hormone Deficiencies Following Radiotherapy for Acromegaly or Cushing's Disease
por: Shen, Angeline, et al.
Publicado: (2019)

MON-255 Oral Contraceptive Pills Mask an Aggressive Crooke’s Cell Pituitary Adenoma
por: Gnanapragasam, Helen Prathiba, et al.
Publicado: (2020)

MON-407 Tumor Control after Radiotherapy and Temozolomide in a Cushing's Disease Patient with Giant Aggressive Pituitary Tumor
por: Valente do Couto, Hugo, et al.
Publicado: (2019)

MON-410 Ectopic ACTH- Secreting Tumor Causing Rapidly Progressive Cushing’s Syndrome Remains an Elusive Localization Diagnosis
por: Anaya Noubleau, Axa, et al.
Publicado: (2019)

MON-295 Desmopressin Test in Silent Corticothoph Pituitary Adenomas, a Preliminary Study - a Comparison with Cushing Disease
por: Huayllas, Martha Katherine, et al.
Publicado: (2020)

MON-440 Cyberknife Radiosurgery for Functional and Non-Functional Pituitary Adenomas: Long-Term Single-Center Experience
por: Yuen, Kevin, et al.
Publicado: (2019)

MON-444 Defining Remission In Cushing Syndrome After Tumor Resection In Cases Of Non-suppressed Postoperative Serum Cortisol Levels
por: McGlotten, Raven, et al.
Publicado: (2019)

MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia
por: Castlen, Joseph, et al.
Publicado: (2019)

MON-LB51 Stimulation for Bilateral Inferior Petrosal Sinus Sampling May Be Unnecessary for Diagnosis of ACTH Dependent Cushing Syndrome
por: Builes-barrera, Carlos Alfonso, et al.
Publicado: (2020)

MON-322 The Characteristic of Reproductive Disorders in Women with ACTH-Dependent Cushing Syndrome in the Republic of Uzbekistan (RUz) and Republic of Karakalpakstan (RKK)
por: Khalimova, Zamira Yusufovna, et al.
Publicado: (2020)

MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study
por: Zacharieva, Sabina Z, et al.
Publicado: (2020)

MON-LB074 Ultrasonography May Reliably Assess Muscle Architecture in Patients with Cushing's Syndrome in Remission: Comparison with Gold-Standard Muscle MRI
por: Martel, Luciana, et al.
Publicado: (2019)

MON-LB073 The Serum Creatinine to Serum Cystatin C Ratio Is a Reliable Surrogate Marker of Sarcopenia in Patients with Cushing's Syndrome in Remission
por: Martel, Luciana, et al.
Publicado: (2019)

SAT-413 Examining Alterations to Arcuate Nucleus NPY Neurons and Their Neural Projections in a Mouse Model of PCOS
por: Marshall, Christopher, et al.
Publicado: (2019)

SAT-279 Crooke’s Cell Adenoma- an Aggressive Form of Cushing’s Disease
por: Radovanovic, Natasa, et al.
Publicado: (2020)

MON-282 Treatment of Hyperprolactinemia with Ropinirole: An Open-Label Dose Escalation Study
por: Tsang, Amanda, et al.
Publicado: (2020)

THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program
por: Newell-Price, John, et al.
Publicado: (2023)

LBMON177 Dosing And Titration Of Osilodrostat In A Real-world Cohort Of US Patients With Endogenous Cushing's Disease: Analysis Of The ILLUSTRATE Study
por: Ioachimescu, Adriana Gabriela, et al.
Publicado: (2022)

SAT-256 The Ever Confusing Cushing’s Work Up: Is It Real? Is It Pseudo Cushing’s’? Or Could It Be Factitious
por: Ghalib, Luma, et al.
Publicado: (2020)

MON-LB079 A Multicenter, Randomized, Open-Label, Phase IV Study Investigating Management of Pasireotide-Associated Hyperglycemia with Incretin-Based Therapy or Insulin in Patients with Acromegaly or Cushing's Disease (CD)
por: Samson, Susan, et al.
Publicado: (2019)

MON-430 To B, or Not to B
por: Pradeep, Pallavi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e2ueaittl841mt0djms01od9lh